Chestnut Hill, MA, United States of America

Hemant Kumar Roy

This inventor holds 12 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Northwestern University, Northshore University Healthsystem, Avi Biopharma, Inc.. Active years: 2008-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hemant Kumar Roy. Retrieved from https://idiyas.com/inventor/hemant-kumar-roy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 6)

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 173(Granted Patents)

Location History:

Highland Park, IL (US) (2008 - 2020)
Chestnut Hill, MA (US) (2016 - 2023)

Company Filing History:

10 out of 2,221

Northwestern University

patents

8 out of 38

Northshore University Healthsystem

Unicorn Therapeutics, LLC

patent

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252522 - Myokines for treating cell proliferative and metabolic diseases and disorders (2025-03-18),

2. 11560414 - Kits comprising myokines and platinum-based chemotherapeutic agents for treating colorectal cancer (2023-01-24),

3. 10898547 - Method of treatment of breast or colon cancer by administering muscle stimulated myokines (2021-01-26),

4. 10584389 - Cancer screening by detection of ultrastructural and molecular markers (2020-03-10),

5. 9783855 - Cancer screening by detection of ultrastructural and molecular markers (2017-10-10),

6. 9314164 - Method of using the detection of early increase in microvascular blood content to distinguish between adenomatous and hyperplastic polyps (2016-04-19),

7. 9090933 - Cancer screening by detection of ultrastructural and molecular markers (2015-07-28),

8. 8735075 - Cancer screening by detection of ultrastructural and molecular markers (2014-05-27),

9. 8131348 - Systems, methods and apparatuses of elastic light scattering spectroscopy and low coherence enhanced backscattering spectroscopy (2012-03-06),

10. 7800746 - Method for identifying refractive-index fluctuations of a target (2010-09-21),

11. 7652772 - Systems, methods, and apparatuses of low-coherence enhanced backscattering spectroscopy (2010-01-26),

12. 7402574 - Antisense composition and method for treating cancer (2008-07-22),

Title: Hemant Kumar Roy: Innovator in Myokine Research

Introduction

Hemant Kumar Roy, based in Chestnut Hill, MA, is a distinguished inventor known for his significant contributions in the field of biotechnology. With an impressive portfolio of 12 patents, Roy has dedicated his career to advancing the understanding and treatment of cell proliferative and metabolic diseases.

Latest Patents

Among his latest groundbreaking patents, Roy has developed compositions comprising myokines for treating various cell proliferative and metabolic diseases and disorders. One such patent focuses on myokines having a molecular weight of greater than about 10 kDa, including myostatin and metrnl. These innovative compositions are designed to treat or prevent debilitating conditions such as cancer, diabetes, non-alcoholic fatty liver disease, and heart disease. Additionally, Roy has patented kits that incorporate myokines and platinum-based chemotherapeutic agents specifically for targeting colorectal cancer, again highlighting the vast potential of myokine research in therapeutic applications.

Career Highlights

Hemant Kumar Roy has been associated with notable institutions, including Northwestern University and Northshore University Healthsystem. His work in these esteemed organizations has enabled him to forge a strong foundation in medical research, particularly focusing on the therapeutic applications of myokines.

Collaborations

Throughout his career, Roy has collaborated with prominent colleagues, including Vadim Backman and Hariharan Subramanian. These partnerships have contributed significantly to his research efforts and enhanced the impact of his innovations in the field.

Conclusion

With an accomplished background and a firm commitment to addressing complex health issues, Hemant Kumar Roy continues to be a leading figure in myokine research. His patents not only reflect his inventive spirit but also hold promise for improving treatment strategies for various metabolic and cell proliferative diseases. As research progresses, Roy's inventions are likely to play a pivotal role in advancing medical science and patient care.

Profile summary based on public USPTO records.